The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a ...

Boston, July 10, 2026 (GLOBE NEWSWIRE) -- The cardiovascular drug development landscape is undergoing a fundamental transformation as artificial intelligence technologies attract unprecedented ...

The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease ...

AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought "untreatable." A new article published in Frontiers in Science says these ...

A drug that heart doctors widely expected to become the next major weapon against heart attacks has failed in a large ...

Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...

Drug development is among the slowest, most failure-prone processes in modern science, with about 90% of drug candidates never reaching the market. Today, artificial intelligence methods have ...

Sept 4 (Reuters) - Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a ...

RNA-based drugs are emerging as the drug of the future for a wide range of diseases, but they are difficult and ...

Cardiovascular disease drugs continue to rank among the most prescribed medicines, but there’s still plenty of unmet medical need. Many of these products are one-size-fits all and they manage symptoms ...

A recent study shows that computer algorithms can be used to find molecules that can be developed into anti-inflammatory drugs. In the article, the researchers also describe how the same strategy can ...